NASDAQ$NVCT
Nuvectis Pharma Inc · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Briefing
Nuvectis Pharma reported Q3 2025, a net loss of $7.5M.
For Q3 2025, Nuvectis Pharma reported a net loss of $7.5M. Management discussed operating trends, liquidity, and priorities as disclosed in the quarterly filing.
- Net loss $7.5M.
- Nuvectis Pharma updated strategic and capital priorities in the filing.
- Nuvectis Pharma updated strategic and capital priorities in the filing.
Headline financials
Revenue & EPS history
Nuvectis Pharma · Revenue · Quarterly
$0
Forward guidance
The filing discusses Nuvectis Pharma's outlook, capital deployment, and key risks without relying solely on numeric EPS guidance.
Tailwinds
- Nuvectis Pharma cited execution on strategic priorities in the filing.
- Balance sheet and liquidity support continued operations.
- Pipeline milestones and partnerships remain key value drivers.
Headwinds
- GAAP profitability remained under pressure in the quarter.
- Macro, competitive, and cost pressures may affect margins.
- Segment mix and one-time items can affect comparability.
- Pre-commercial or early-stage spend continues ahead of sustainable product revenue.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2025
+2.4%
Avg return
Earnings day
+7.2%
Avg return
5 days after
-3.7%
Avg return
30 days after
65%
13 / 20 earnings
Positive
+29.2%
Q3 2024
Best reaction
-14.9%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +9.4% | +31.6% | +8.8% | |
| Q4 2026 | +0.5% | +0.2% | +3.3% | |
| Q3 2025 | -7.9% | -3.5% | +6.1% | |
| Q2 2025 | -5.4% | -17.7% | -10.6% | |
| Q1 2025 | +6.4% | +8.3% | -9.4% | |
| Q4 2024 | -5.8% | -9.1% | +31.1% | |
| Q3 2024 | +29.2% | +71.3% | -24.6% | |
| Q1 2024 | -14.9% | -15.3% | -13.6% | |
| Q4 2023 | -4.5% | -0.4% | -25.1% | |
| Q3 2023 | -7.9% | -6.6% | -8.4% | |
| Q2 2023 | +1.4% | +1.1% | -7.0% | |
| Q1 2023 | +5.8% | +6.3% | +14.0% | |
| Q4 2022 | -7.1% | -9.5% | +9.2% | |
| Q3 2021 | +0.9% | -3.5% | +7.7% | |
| Q3 2022 | +0.9% | -3.5% | +7.7% | |
| Q2 2021 | +1.1% | +10.1% | -0.6% | |
| Q2 2022 | +2.6% | -3.0% | -3.7% | |
| Q1 2021 | +18.8% | +28.8% | -24.4% | |
| Q4 2021 | +18.8% | +33.6% | -15.6% | |
| Q1 2022 | +5.4% | +25.2% | -19.4% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro